An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study
Phase 4
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Neoplasms
Both
Neoplasms
Trial Information
An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study
Inclusion Criteria:
- Adult patients, >/=18 years of age
- Patients with solid tumours
- Patient is treated with Avastin at the end of a Roche/Genentech sponsored parent
trial and continues to have benefit from Avastin treatment
- Eligible for continuation of Avastin treatment at the end of a parent trial
- Able to comply with this extension study protocol (MO25757)
Exclusion Criteria:
- Evidence of disease progression
- Evidence of any adverse event potentially attributable to Avastin, for which
permanent treatment discontinuation is recommended
- A treatment interruption with Avastin of more than 42 days since the last
administration of Avastin in a parent trial
- Any other disease that would put the patient at high risk for treatment-related
complications
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety: Incidence of Adverse Events
Outcome Time Frame:
Approximately 5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Czech Republic: State Institute for Drug Control
Study ID:
MO25757
NCT ID:
NCT01588184
Start Date:
July 2012
Completion Date:
June 2017
Related Keywords:
- Neoplasms
- Neoplasms
Name | Location |
|---|
